Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been assigned a consensus rating of “Hold” from the twenty-six brokerages that are presently covering the firm. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $472.00.

Several equities analysts have recently weighed in on REGN shares. Vetr downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 price target for the company. in a report on Wednesday, July 27th. Cowen and Company restated a “hold” rating and set a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $505.00 to $448.00 in a report on Friday, August 5th. Canaccord Genuity restated a “hold” rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Brean Capital restated a “buy” rating and set a $489.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th.

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 2,000 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total value of $858,680.00. Following the completion of the sale, the director now directly owns 36,500 shares in the company, valued at approximately $15,670,910. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $450.00, for a total value of $956,250.00. Following the completion of the sale, the director now owns 15,125 shares of the company’s stock, valued at $6,806,250. The disclosure for this sale can be found here. 10.40% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. AMP Capital Investors Ltd boosted its stake in shares of Regeneron Pharmaceuticals by 15.7% in the first quarter. AMP Capital Investors Ltd now owns 29,898 shares of the biopharmaceutical company’s stock valued at $10,753,000 after buying an additional 4,060 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 7.7% in the first quarter. Envestnet Asset Management Inc. now owns 17,355 shares of the biopharmaceutical company’s stock valued at $6,255,000 after buying an additional 1,245 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $207,000. A.R.T. Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $1,185,000. Finally, Magnetar Financial LLC boosted its stake in shares of Regeneron Pharmaceuticals by 160.0% in the first quarter. Magnetar Financial LLC now owns 1,188 shares of the biopharmaceutical company’s stock valued at $428,000 after buying an additional 731 shares in the last quarter. Institutional investors and hedge funds own 68.58% of the company’s stock.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 397.48 on Monday. The firm’s 50-day moving average is $380.96 and its 200 day moving average is $388.24. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $584.59. The stock has a market capitalization of $41.67 billion, a P/E ratio of 57.99 and a beta of 1.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating the consensus estimate of $2.73 by $0.40. The business earned $1.22 billion during the quarter, compared to analyst estimates of $1.29 billion. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.47 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post $11.73 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.